<p>对于精明的投资者来说，被低估的生物科技股将始终具有吸引力。</p>
<p>生物科技领域正在迅速发展，制药巨头们不知疲倦地加强其产品线和技术。我们看到基因编辑变得更加精细，对先进医疗保健的需求不断增长。此外，人工智能在药物发现中的新角色可能会为生物科技公司带来更多机会。</p>
<p>然而，这个行业可能非常波动：临床试验和 FDA 批准的风险对一家公司来说是成败的关键。尽管如此，这个领域为潜在的有利投资提供了激动人心的道路。</p>
<p>在正确的时间购买适当的生物科技股票可能会带来爆炸性的收益。事实上，文章中涵盖的股票根据分析师共识预测至少有 80% 的上涨空间。因此，现在是在这些股票持续上涨之前跟进的最佳时机。</p>
<h2>Viking 治疗（VKTX）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Shutterstock</p>
<p><strong>Viking 治疗</strong>（纳斯达克：<strong>VKTX</strong>）可以说是新兴的减肥药市场中最具爆发力的参与者。由于其减肥候选药 VK2735 取得了出色的成果，VKTX 股票今年迄今已飙升 168%。此外，根据 <strong>高盛</strong> 的数据，到 2030 年，减肥市场的价值可能达到约 1300 亿美元，这预示着 Viking 未来有巨大的增长空间。</p>
<p>迄今为止的数据显示，Viking 可能有重大发现。VK2735 的口服形式在第一阶段试验中仅 28 天后就显示出了 3.3% 的体重减轻。此外，我们听说一家制药巨头有可能收购该公司，这可能成为 VKTX 股票未来的主要推动因素。无论是继续保持独立还是以溢价价格被收购，对其股东来说未来看起来非常令人鼓舞。此外，10 位华尔街分析师将该股票评为 ‘强烈买入’，并预计有 89% 的上涨潜力。</p>
<h2>Altimmune（ALT）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：WHYFRAME / Shutterstock.com</p>
<p><strong>Altimmune</strong>（纳斯达克：<strong>ALT</strong>）是另一家有前景的减肥领域参与者，可能在未来 12 个月内为投资者带来丰厚回报。</p>
<p>在减肥领域的一小部分新兴明星中，Altimmune 以其创新治疗 pemvidutide 脱颖而出。根据最新试验数据，pemvidutide 在减肥的同时帮助保持瘦体重。48 周的试验显示，大约 74.5% 的体重减轻与脂肪组织有关，其余与瘦体重有关。这使 Altimmune 在竞争中占据优势，特别是与 GLP-1 激动剂相比，后者与更高比例的肌肉流失相关。</p>
<p>此外，该药物在减肥之外显示出了潜力，减少肝脂肪并治疗乙型肝炎。此外，FDA 对该药物在治疗一种脂肪肝病变体的快速通道指定突显了其潜力。因此，五位华尔街分析师将其评为 ‘强烈买入’，并预计有 171% 的强劲上涨潜力。</p>
<h2>Zura Bio（ZURA）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Shutterstock</p>
<p><strong>Zura Bio</strong>（纳斯达克：<strong>ZURA</strong>）是另一家在治疗免疫和炎症性疾病方面不断取得重大进展的临床阶段生物科技公司。与文章中讨论的其他股票不同，ZURA 股票在过去一年中基本保持横盘。然而，该股票的上涨潜力令人难以忽视，拥有三个准备进入第二阶段试验的有前途的资产。</p>
<p>其中，tibulizumab 是该公司的首选药物候选，已进入第 II 期试验，用于治疗慢性炎症性皮肤病汗腺脓肿（HS）。此外，该候选药将于今年晚些时候进行系统性硬皮病（SSc）的第 II 期临床试验。</p>
<p>因此，通过专注于满足免疫和炎症性疾病领域未满足的医疗需求，Zura 在生物科技领域可能是一个重大机遇。此外，华尔街的共识预测显示，其股价有望从当前水平上涨 478%。</p>
<p>_在发布日期，Muslim Farooque 在本文提及的证券中没有（直接或间接）任何持仓。本文中表达的观点属于作者本人，遵守 InvestorPlace.com 的发布准则。</p>
<p>_在发布日期，负责编辑在本文提及的证券中没有（直接或间接）任何持仓。</p>
<p>Muslim Farooque 是一位热心的投资者和乐观主义者。作为一名终身游戏玩家和科技爱好者，他特别喜欢分析科技股。Muslim 拥有牛津布鲁克斯大学应用会计学学士学位。</p>
<p>医疗保健，生物科技</p>

ZURA

Viking治疗

<p>本文讨论了具有突破潜力的被低估生物科技股。生物科技行业正在迅速发展，基因编辑和人工智能在药物发现中的作用不断取得进展。在正确的时间投资于正确的生物科技股票可能会带来爆炸性收益。文章重点介绍了三家特定股票：Viking 治疗（VKTX）、Altimmune（ALT）和 Zura Bio（ZURA），据分析师称，每家公司都有显著的上涨潜力。这些股票专注于减肥治疗、免疫和炎症性疾病，并在其研发管线中拥有有前途的药物候选品</p>

<p>Undervalued biotech stocks will always be relevant for the savvy investor.</p>
<div class="lb-trans"><p>对于精明的投资者来说，被低估的生物科技股将始终具有吸引力。</p>
</div><p>The biotech world is evolving rapidly, with pharmaceutical giants tirelessly building on their pipelines and technologies. We’re seeing gene editing become more refined, with a growing appetite for advanced healthcare. On top of that, AI’s new role in drug discovery could take things up a notch or two for biotech players.</p>
<div class="lb-trans"><p>生物科技领域正在迅速发展，制药巨头们不知疲倦地加强其产品线和技术。我们看到基因编辑变得更加精细，对先进医疗保健的需求不断增长。此外，人工智能在药物发现中的新角色可能会为生物科技公司带来更多机会。</p>
</div><p>However, the industry can be incredibly volatile: The stakes of clinical trials and FDA approvals are a make-or-break situation for a company, for example. Nonetheless, the landscape offers a thrilling path to potentially rewarding investments.</p>
<div class="lb-trans"><p>然而，这个行业可能非常波动：临床试验和 FDA 批准的风险对一家公司来说是成败的关键。尽管如此，这个领域为潜在的有利投资提供了激动人心的道路。</p>
</div><p>Snapping the right biotech stocks to buy at the right time can result in explosive gains. In fact, the stocks covered in the article offer at least an 80% upside based on analyst consensus estimates. Thus, now is the prime time to jump on these stocks before a sustained rally ahead.</p>
<div class="lb-trans"><p>在正确的时间购买适当的生物科技股票可能会带来爆炸性的收益。事实上，文章中涵盖的股票根据分析师共识预测至少有 80% 的上涨空间。因此，现在是在这些股票持续上涨之前跟进的最佳时机。</p>
</div><h2>Viking Therapeutics (VKTX)</h2>
<div class="lb-trans"><h2>Viking 治疗（VKTX）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>来源：Shutterstock</p>
</div><p><strong>Viking Therapeutics</strong> (NASDAQ: <strong>VKTX</strong>) is arguably the most explosive entrant in the burgeoning weight loss drug market. VKTX stock has surged 168% year-to-date (YTD) due to exceptional results from its weight loss candidate, VK2735. Moreover, according to <strong>Goldman Sachs</strong>, the weight loss market could be worth roughly $130 billion by 2030, pointing to a massive growth runway ahead for Viking.</p>
<div class="lb-trans"><p><strong>Viking 治疗</strong>（纳斯达克：<strong>VKTX</strong>）可以说是新兴的减肥药市场中最具爆发力的参与者。由于其减肥候选药 VK2735 取得了出色的成果，VKTX 股票今年迄今已飙升 168%。此外，根据 <strong>高盛</strong> 的数据，到 2030 年，减肥市场的价值可能达到约 1300 亿美元，这预示着 Viking 未来有巨大的增长空间。</p>
</div><p>The data so far shows that Viking could be on to something huge. The oral form of VK2735 showed a 3.3% reduction in body weight after just 28 days in Phase 1 trials. Additionally, we’re hearing rumors of a pharma giant potentially acquiring the company, which could be a major catalyst for VKTX stock ahead. Whether it remains Viking independent or is snapped up at a premium price, the future looks incredibly encouraging for its shareholders. Also, 10 Wall Street analysts rate the stock as a ‘strong buy’ while projecting an 89% upside potential.</p>
<div class="lb-trans"><p>迄今为止的数据显示，Viking 可能有重大发现。VK2735 的口服形式在第一阶段试验中仅 28 天后就显示出了 3.3% 的体重减轻。此外，我们听说一家制药巨头有可能收购该公司，这可能成为 VKTX 股票未来的主要推动因素。无论是继续保持独立还是以溢价价格被收购，对其股东来说未来看起来非常令人鼓舞。此外，10 位华尔街分析师将该股票评为 ‘强烈买入’，并预计有 89% 的上涨潜力。</p>
</div><h2>Altimmune (ALT)</h2>
<div class="lb-trans"><h2>Altimmune（ALT）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: WHYFRAME / Shutterstock.com</p>
<div class="lb-trans"><p>来源：WHYFRAME / Shutterstock.com</p>
</div><p><strong>Altimmune</strong>(NASDAQ: <strong>ALT</strong>) is another promising player in the weight loss sphere that could potentially reward investors handsomely over the next 12 months.</p>
<div class="lb-trans"><p><strong>Altimmune</strong>（纳斯达克：<strong>ALT</strong>）是另一家有前景的减肥领域参与者，可能在未来 12 个月内为投资者带来丰厚回报。</p>
</div><p>Among a handful of emerging stars in the weight loss niche, Altimmune stands out with its innovative treatment, pemvidutide. According to data from its latest trials, pemvidutide helped preserve lean mass while cutting weight. The 48-week trial showed that roughly 74.5% of the weight loss was linked to fat tissue, while the rest was connected to lean mass. This gives Altimmune a leg up over its competition, particularly GLP-1 agonists, which are associated with higher rates of muscle loss.</p>
<div class="lb-trans"><p>在减肥领域的一小部分新兴明星中，Altimmune 以其创新治疗 pemvidutide 脱颖而出。根据最新试验数据，pemvidutide 在减肥的同时帮助保持瘦体重。48 周的试验显示，大约 74.5% 的体重减轻与脂肪组织有关，其余与瘦体重有关。这使 Altimmune 在竞争中占据优势，特别是与 GLP-1 激动剂相比，后者与更高比例的肌肉流失相关。</p>
</div><p>Moreover, the drug has shown promise beyond weight loss, reducing liver fat, and treating hepatitis B. Additionally, the FDA’s fast-track designation for the drug in treating a variant of fatty liver disease underscores its potential. Consequently, five Wall Street analysts rate it a ‘strong buy’ and project a robust 171% upside potential.</p>
<div class="lb-trans"><p>此外，该药物在减肥之外显示出了潜力，减少肝脂肪并治疗乙型肝炎。此外，FDA 对该药物在治疗一种脂肪肝病变体的快速通道指定突显了其潜力。因此，五位华尔街分析师将其评为 ‘强烈买入’，并预计有 171% 的强劲上涨潜力。</p>
</div><h2>Zura Bio (ZURA)</h2>
<div class="lb-trans"><h2>Zura Bio（ZURA）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>来源：Shutterstock</p>
</div><p><strong>Zura Bio</strong> (NASDAQ: <strong>ZURA</strong>) is another clinical-stage biotech that continues to make major strides in the treatment of immune and inflammatory disorders. Unlike other stocks discussed in the article, ZURA stock has moved mostly sideways in the past year. However, the upside potential in the stock is tough to overlook, with three promising assets ready for Phase 2 trials.</p>
<div class="lb-trans"><p><strong>Zura Bio</strong>（纳斯达克：<strong>ZURA</strong>）是另一家在治疗免疫和炎症性疾病方面不断取得重大进展的临床阶段生物科技公司。与文章中讨论的其他股票不同，ZURA 股票在过去一年中基本保持横盘。然而，该股票的上涨潜力令人难以忽视，拥有三个准备进入第二阶段试验的有前途的资产。</p>
</div><p>Among these, tibulizumab is the firm’s top drug candidate, entering Phase II trials for treating hidradenitis suppurativa (HS), a chronic inflammatory skin condition. Moreover, Phase II clinical trials are scheduled for later this year for its candidate covering systemic scleroderma (SSc), a chronic autoimmune disease.</p>
<div class="lb-trans"><p>其中，tibulizumab 是该公司的首选药物候选，已进入第 II 期试验，用于治疗慢性炎症性皮肤病汗腺脓肿（HS）。此外，该候选药将于今年晚些时候进行系统性硬皮病（SSc）的第 II 期临床试验。</p>
</div><p>Hence, Zura could potentially be a major opportunity in the biotech space through its focused approach to catering to unmet medical needs in immune and inflammatory disorders. Additionally, Wall-Street consensus estimates point to a whopping 478% upside from current levels.</p>
<div class="lb-trans"><p>因此，通过专注于满足免疫和炎症性疾病领域未满足的医疗需求，Zura 在生物科技领域可能是一个重大机遇。此外，华尔街的共识预测显示，其股价有望从当前水平上涨 478%。</p>
</div><p><em>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines</em>.</p>
<div class="lb-trans"><p>_在发布日期，Muslim Farooque 在本文提及的证券中没有（直接或间接）任何持仓。本文中表达的观点属于作者本人，遵守 InvestorPlace.com 的发布准则。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p>_在发布日期，负责编辑在本文提及的证券中没有（直接或间接）任何持仓。</p>
</div><p>Muslim Farooque is a keen investor and an optimist at heart. A life-long gamer and tech enthusiast, he has a particular affinity for analyzing technology stocks. Muslim holds a bachelor’s of science degree in applied accounting from Oxford Brookes University.</p>
<div class="lb-trans"><p>Muslim Farooque 是一位热心的投资者和乐观主义者。作为一名终身游戏玩家和科技爱好者，他特别喜欢分析科技股。Muslim 拥有牛津布鲁克斯大学应用会计学学士学位。</p>
</div><p>Healthcare, Biotech</p>
<div class="lb-trans"><p>医疗保健，生物科技</p>
</div>

3 只具有突破潜力的被低估的生物科技股